The Food and Drug Administration (FDA) has given the Blanchette Rockefeller Neurosciences Institute (BRNI) the go-ahead to conduct Phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease patients. The drug showed pre-clinical efficacy to not only treat Alzheimer's disease symptoms, but also its underlying causes. "We are very excited about the FDA's agreement for BRNI to move forward with clinical trials," said Dr. Daniel Alkon, Scientific Director of BRNI.